Dexin X. Yu

Hefei, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications

ENPP3 drives ccRCC progression by cGAMP hydrolysis and STING-IFN suppression.

ENPP3 drives ccRCC progression by cGAMP hydrolysis and STING-IFN suppression.

Journal: Cancer biology & therapy
Published: February 20, 2026

Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial.

Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial.

Journal: Clinical and translational medicine
Published: December 15, 2025

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology
Published: March 18, 2025

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Journal: BMC medicine
Published: October 14, 2024

Effectiveness, pharmacokinetics, and safety of triptorelin acetate microspheres in patients with locally advanced and metastatic prostate cancer.

Effectiveness, pharmacokinetics, and safety of triptorelin acetate microspheres in patients with locally advanced and metastatic prostate cancer.

Journal: Therapeutic advances in medical oncology
Published: May 28, 2024

The application of the "perinephric fat wrapping" technique with oral mucosal graft for the management of ureter repair and reconstruction.

The application of the "perinephric fat wrapping" technique with oral mucosal graft for the management of ureter repair and reconstruction.

Journal: World journal of urology
Published: March 27, 2024

Case report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level.

Case report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level.

Journal: Frontiers in oncology
Published: March 21, 2024

Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.

Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.

Journal: Discover oncology
Published: February 26, 2024

Flexible ureteroscopy in Chinese air force pilots with renal calculi: a cohort study at a single medical centre.

Flexible ureteroscopy in Chinese air force pilots with renal calculi: a cohort study at a single medical centre.

Journal: BMJ military health
Published: February 25, 2024

Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.

Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.

Journal: Nature cancer
Published: December 09, 2023

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 03, 2023

ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.

ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.

Journal: BMC cancer
Published: January 27, 2023
Showing 1-12 of 71

Last Updated: 09/26/2026